EICHOR
● Active Not Recruiting
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Condition: Follicular Lymphoma (FL) · Sponsor: Genmab
About this study
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (273)
| The University of Arizona Cancer Center - North Campus /ID# 228862 | Tucson, Arizona, United States | — |
| University of Arkansas for Medical Sciences /ID# 227198 | Little Rock, Arkansas, United States | — |
| Alta Bates Summit Medical Center for Research /ID# 229428 | Berkeley, California, United States | — |
| Beverly Hills Cancer Center /ID# 231535 | Beverly Hills, California, United States | — |
| Long Beach Memorial Medical Ct /ID# 228997 | Long Beach, California, United States | — |
| University of Southern California /ID# 227195 | Los Angeles, California, United States | — |
| Valkyrie Clinical Trials /ID# 268502 | Los Angeles, California, United States | — |
| Duplicate_Emory University /ID# 227299 | Atlanta, Georgia, United States | — |
| Hawaii Cancer Care - Waterfront Plaza /ID# 262448 | Honolulu, Hawaii, United States | — |
| Northwestern University Feinberg School of Medicine /ID# 227248 | Chicago, Illinois, United States | — |
| Goshen Center for Cancer Care /ID# 227189 | Goshen, Indiana, United States | — |
| Community Health Network, Inc. /ID# 259756 | Indianapolis, Indiana, United States | — |
+ 261 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05409066